Sunil Healthcare
- Market cap
- ₹ 72 Cr.
- P/E
- 18.6x
- P/B
- 0.94x
- 52-week range
- 60 – 82
- ROE
- 6%
- ROCE
- 6.5%
- Dividend yield
- 0%
- Debt / equity
- 0.8
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sunil Healthcare Limited is an India-based company, which is engaged in manufacturing hard shell capsules. The Company manufactures empty hard gelatin, hydroxypropyl methylcellulose (HPMC) capsule shells and ayurvedic medicines. The Company offers various capsules, including BSE/TSE Free Capsules, Pearl Capsules, Liquid Fill Capsules, Stick Free Capsules, Flavored Capsules, SLS Free Capsules, Natural Color Capsules, Non-Azo Capsules and Preservative Free Capsules. Its hard gelatin capsule shells are available in nine sizes, such as 00, 0SEL, 0EL, 0,1,2,3, 4, 5. Pullulan Capsules are a type of vegetable capsule made from pullulan. The Vegetable Capsules are commonly used as an option for gelatin because of its vegetarian source and its physical appearance to gelatin. The Company offers empty gelatin capsules that are flavorless, unscented, and colorless, making them simple to consume. Its product range caters to the pharma and food supplement industries.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sunil Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)18.6 against a typical 34.3: cheaper than most peers (1st = cheapest).50th of 220
- Sales growth−16.1% against a typical +15.6% from a year earlier.171st of 197
- Profit growth−49.5% against a typical +18.9% from a year earlier.132nd of 160
- Size₹ 71.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).158th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BB; ISSUER NOT COOPERATING* | Stable | 5 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 5 Oct 2026 | ▼ Downgrade | CARE BB | Medium | CARE | ₹ 57.7 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 23 | 21 | 22 | 20 | 20 | 21 | 23 | 24 | 22 | 20 | 19 |
| Expenses | 22 | 23 | 19 | 19 | 18 | 18 | 18 | 19 | 20 | 18 | 18 | 16 |
| Operating Profit | 1 | −1 | 3 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 2 | 3 |
| OPM % | 5.2% | −2.8% | 12.6% | 10.3% | 11.4% | 13.2% | 14.3% | 14.4% | 16.7% | 16.6% | 9.8% | 15.4% |
| Other Income | 0 | 3 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit before tax | −1 | −0 | 0 | −1 | −1 | −0 | 0 | 1 | 1 | 1 | −1 | 0 |
| Tax % | −25.3% | −48.7% | 5.9% | 6.3% | 7.7% | 57.1% | −28.6% | 11.7% | 23.7% | 31% | −259% | −130% |
| Net Profit | −1 | −0 | 0 | −1 | −1 | −1 | 0 | 1 | 1 | 1 | 2 | 0 |
| EPS in Rs | −1.07 | −0.2 | 0.15 | −0.67 | −0.54 | −0.53 | 0.35 | 0.89 | 0.98 | 0.58 | 1.48 | 0.45 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- −1%
- 3 Years
- −7%
- TTM
- −1%
- 10 Years
- —
- 5 Years
- 55%
- 3 Years
- −15%
- TTM
- 1,950%
- 10 Years
- −3%
- 5 Years
- 16%
- 3 Years
- 8%
- TTM
- —
- 10 Years
- 3%
- 5 Years
- 5%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sunil Healthcare | ₹ 67.90 | ₹ 72 Cr. | 18.6x | 0.9x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.6x | 5.6x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 87x | 13.6x | — | 26.1% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 22.3x | 4.5x | — | 15.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.4x | 3.4x | — | 11.9% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.7x | 19.7x | — | 13.7% |
Management
- Anil Kumar Khaitan
- Executive Chairman of the Board, Managing Director, Chief Executive Officer
- Pawan Rathi
- Chief Financial Officer
- Ishan Khaitan
- President Operation and Marketing
- Santosh Deshprabhu
- Senior Vice President and Plant Head
- Satyendu Pattnaik
- Compliance Officer, Company Secretary
- Sarita Khaitan
- Chief Strategic Officer
Prices are delayed and for information only. Nothing on this page is investment advice.